Please login to the form below

Not currently logged in
Email:
Password:

Sepracor and Eisai partner to develop and commercialise Lunesta in Japan

Sepracor signs an agreement with Eisai for the development and commercialisation of its sleep aid product Lunesta  in Japan


US-based Sepracor has signed an agreement with Japanese pharmaceutical firm Eisai for the development and commercialisation of Sepracor's sleep aid treatment Lunesta (eszopiclone) in Japan.

Per the agreement, Eisai will be responsible for completing the remaining clinical trials necessary for attaining marketing approval from the Japanese regulatory authorities, and contingent on regulatory approval, commercialisation of the product in Japan. Sepracor has said that the Japanese marketing application will be submitted in 2010/2011.

Sepracor will receive an initial milestone payment and subsequent payments upon accomplishment of various development, regulatory and pricing milestones, as well as royalties on product sales and compensation for providing the product's active ingredient.

Lunesta has been commercially available in the US since 2005 for the treatment of insomnia and posted sales of USD 566.8m in FY06. The sedative hypnotic market in Japan was valued at around USD 500m in 2006.

30th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics